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Abstract 
Background. The GH2000 score has been developed as a powerful and unique technique for 
the detection of growth hormone misuse by sportsmen and women. With the collection and 
establishment of an increasingly large data base it has become apparent that the score 
shows a positive age effect in the male athlete population, which could potentially place 
older male athletes at a disadvantage.  
Methods. We have used results from residual analysis of the general linear model to show 
that the residual of the GH2000 score when regressed on the mean-age centered age is the 
right way to proceed to correct this bias. As six GH2000 scores are possible depending on 
the assays used for determining IGF-I and P-III-NP, methodology had to be explored for 
including six different age effects into a unique residual. Meta-analytic techniques have 
been utilized to find a summary age effect. 
Results. This form of age-adjusted GH2000 score, a form of residual, has similar mean and 
variance as the original GH2000 score and, hence, the developed decision limits show 
negligible change when compared to the decision limits based on the original score. We also 
show that any further scale-transformation will not change the adjusted score any more. 
Hence the suggested adjustment is optimal for the given data.  The summary age effect is 
homogeneous across the six scores, and so the generic adjustment of the GH2000 score 
formula is justified. 
Conclusions. A final revised GH2000 score formula is provided which is independent of the 
age of the athlete under consideration.  
Key words: GH2000 score, adjusting for age effects, meta-analysis of scores, centering and 
norming of scores 
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Introduction and background 
Growth hormone is a powerful anabolic agent of considerable therapeutic value but also 
misused in sport. In order to preserve the fairness of competition there is a need for 
methods to detect its misuse. Two methods are presently available and approved by the 
World Anti-Doping Agency (WADA); the isoform test developed by Strasburger, Wu and 
Bidlingmaier and the GH2000 biomarker test developed by the GH2000 and GH-2004 
projects (Holt et al. 2015). The latter method depends upon the measurement of two 
growth hormone (GH) sensitive markers, insulin-like growth factor-I (IGF-I) and the amino-
terminal pro-peptide of type III collagen (P-III-NP). The measured concentrations of the 
biomarkers are combined in sex-specific and age-adjusted discriminant functions, which 
allow for the calculation of a score (the GH2000 score) on which basis the compliance of the 
sample’s analytical result is determined.  
The initial development of the GH2000 score was reported by Powrie et al. (2007) but this 
score was based on immunoassays that are no longer commercially available. Although the 
original discriminant function has remained unchanged, the decision limits have been 
updated as further experience was accumulated and new assays became available 
(Erotokritou-Mulligan et al. 2012 and Holt et al.  2015). Currently, there are three IGF-I 
assays and two P-III-NP assays approved by WADA.  
The IGF-I assays used in this study were: 
 Liquid chromatography-tandem mass spectrometry (LC-MS/MS)  
 Immunotech A15729 IGF-I IRMA (Immunotech SAS, Marseille, France)  
 and  Immunodiagnostic Systems iSYS IGF-I (Immunodiagnostics Systems Limited, 
Boldon, UK)  
The P-III-NP assays used in this analysis were:  
 UniQ™ P-III-NP RIA (Orion Diagnostica, Espoo, Finland) 
 Siemens ADVIA Centaur P-III-NP (Siemens Healthcare Laboratory Diagnostics, 
Camberley, UK) . 
For more details and background on these assays see Holt et al. (2015).   
 
As these assays do not give identical results, different GH2000 scores are obtained with 
each of the combinations and this means that the decision limits are slightly different, 
depending on the assay pair used. 
 
The score itself involves measurement of IGF-I and P-III-NP in a linear way and a term that 
involves age inversely 
   0 1 2 3GH2000 score log IGF-I  log P-III-NP   / age          (1) 
where the coefficients 0 1 2 3, , ,     have different values for male and female athletes.  
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The inverse term for age in (1) is designed to adjust for age so that the score becomes 
independent of age. This is important in order to make the test applicable to athletes of all 
ages. Recent analysis of a combined database of elite athletes (Holt et al. 2015) provides 
evidence that the score is independent of age for the female population whereas it shows a 
linear dependence for male athletes. The combined database contains blood samples of 
athletes collecting at various sporting events including the 2011 International Association of 
Athletics Federations (IAAF) World Athletics Championships in Daegu, South Korea, in the 
following abbreviated as the Daegu-sample.   
Figure 1 shows the scores and their relationship to age in 597 male athletes competing in 
Daegu.  There are 6 scores as there are 3 assays for IGF-I (LC-MS/MS, Immunotech, IDS) and 
2 for P-IIIN-P (Siemens-Centaur, Orion). It is clear from Figure 1 that in all GH2000-scores 
there is a positive age dependency as all linear regression lines show a significant age-effect. 
There is no age effect on the GH2000 scores for the female population of the Daegu-sample 
(data not shown). 
The purpose of this paper is to suggest and discuss statistical methodology for adjusting the 
existing score for the undesirable age-effect. 
 
 
Figure 1:  Scatterplots with regression lines for the six GH-scores available of all male 
athletes in the Daegu-sample in the order of their appearance: Siemens-LC-MS/MS (top-
left), Siemens-Immunotech (top-middle), Siemens-IDS (top-right), Orion-LC-MS/MS (bottom-
left),  Orion-Immunotech (bottom-middle),  Orion-IDS (bottom-right) 
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Methods 
The basics of adjustment 
Consider a response Y  (in our case the GH2000 score) and an effect x  (in our case the age 
of an athlete). Suppose that the response Y  is related to x  by a linear regression model 
      E Y x             
Then, the least-squares estimate of   is given by  
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where the pairs ( , )i iY x represent the n  sample values of Y and x . On this basis we are able 
to construct a response  *Y  adjusting for x  
 * ˆ  Y Y x   .          
The adjusted response *Y is independent of x  as the following analysis shows. Tthis can be 
found in most books on regression but it is mentioned here for completeness. Consider the 
least-squares-estimate of *  in 
  * * *   E Y x   . 
This is given as the least-squares estimate of *  
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. 
Hence *Y is independent of x . A more general result is provided in Appendix A. 
Next, we suggest considering an adjustment of the form 
 
*   ( )Y Y x x   . 
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The benefit of this adjustment lies in the fact that the adjusted score *Y  remains on the 
same level as the original score Y  as 
 
*
( )Y Y x x Y    . 
The process of considering x x  is called centering. Sometimes also norming is considered 
in addition to centering which is ( ) / ( )x x sd x where 2
1
1
( ) ( )
1
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i
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
 . We are not 
considering norming here as this will not lead to any further adjustment.   To see this, 
considered any scale transformation ax  of x . The original model ( )E Y x    becomes 
now * * *( )E Y x   , where *x ax . Then, least squares estimates can be found as 
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Hence the adjusted response 
 * * *
1
    ( )Y Y x Y ax
a
        Y x   
is indeed identical to the original adjustment  Y x  and does not lead to anything new. A 
more general result is provided in Appendix B. Hence we stay with the adjustment  
 *   ( )Y Y x x    
as the final form of adjustment.  
 
Adjusting the GH2000 score 
To adjust the GH2000 score, we consider the regression of the GH2000 score on age. Table 1 
shows 6 age-effects for the 6 GH2000 scores (as there are 2 assays for measuring PIIINP and 
3 assays for measuring IGF-I). 
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Table 1: Estimated  -coefficients of the age-effects for the six GH2000 scores and their 
associated standard errors 
 
GH2000 score  age S.E. 
P-III-NP assay IGF-I assay   
Siemens 
Siemens 
Siemens 
LC-MS/MS 
Immunotech 
IDS 
0.0418 
0.0261 
0.0359 
0.0082 
0.0086 
0.0070 
Orion 
Orion 
Orion 
LC-MS/MS 
Immunotech 
IDS 
0.0363 
0.0202 
0.0318 
0.0077 
0.0085 
0.0077 
 
For simplicity and ease of use by the anti-doping laboratories, it is important that we do not 
create an age adjustment for each assay pairing. Thus we need to include the age 
adjustment within  the generic GH2000 score (independent of the specific assay pairing 
used). To accomplish this task we have applied ideas from meta-analysis. We consider each 
GH2000 score using a specific assay combination as a realisation from multiple possible 
assay combinations. 
This is similar to a meta-analysis approach in which studies aiming to estimate a certain 
effect are considered as realisation from a universe of possible studies. 
Hence we use  
 
1 1
k k
i i i
i i
w w 
 
   
where k =6 is the number of different assay combinations used and ˆi  is the estimated age 
effect, and iw  is the inverse of the estimated variance (the squared values in column 3 of 
table 1). Hence   is an average of the estimated effect.  
Results 
In our case, we find  = 0.032. Figure 2 shows this analysis graphically.  As all assay-specific 
age effects are similar in their standard error, all weights are similar. More details on the 
meta-analysis approach are given in  Appendix C.  
8 
 
 
Figure 2: Meta-analytic results for the six age-effects of the GH2000 scores on age (I-V 
stands for overall inversely weighted and provides the summary estimate of the age-affect); 
more details are given in the appendix 
 
From the meta-analysis, we achieve the formula for the male athletes:  
 GH2000 score-adj = GH2000 score – 0.032 (age - 25.09) 
AS the mean age for male athletes is 25.09 years and the GH2000 is calculated as: 
 GH2000 score = - 6.586 + 2.905 log(P-III-NP) + 2.100 log(IGF-I) – 101.737/age 
the adjusted score formula becomes:  
 GH2000 score-adj = - 5.783 +2.905 log(P-III-NP) + 2.100 log(IGF-I)  
– 101.737/age – 0.032 age.      (2) 
Figure 3 shows a scatterplot of the six age-adjusted GH2000-scores. It clearly shows that the 
age-effect is removed as it is expected from the above theory.  
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Figure 3:  Scatterplots with regression lines for the six age-adjusted GH-scores of all male 
athletes in the Daegu-sample in the order of their appearance: Siemens-LC-MS/MS (top-
left), Siemens-Immunotech (top-middle), Siemens-IDS (top-right), Orion-LC-MS/MS (bottom-
left),  Orion-Immunotech (bottom-middle),  Orion-IDS (bottom-right) 
 
Effect on the current WADA decision limits 
Although this adjustment will lead to changes in the individual GH2000 score of an athlete, 
it has negligible effect on the decision limits. Following Holt et al. (2015) these are 
constructed using the 1 in 10,000 false positive rate as 
 3.72y s u   
where y  and s  are mean and standard deviation of the respective GH2000 score. u  is a 
sample uncertainly term defined as 
 
2 23.72
(1 )
s
u
n n
   
where n  is the sample size.  Table 2 shows the details, in particular, a comparison between 
GH2000 scores with and without adjustment. 
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Table 2: Descriptive statistics including decision limits for the 6 unadjusted and adjusted 
GH2000 scores 
 
Assay pair  n mean s Mean+3.72*s U DL 
P-III-NP IGF-I        
Siemens LC-MS 
 
Unadjusted 
Adjusted 
947 
947 
6.5393 
6.5382 
1.2412 
1.2424 
11.1566 
11.1599 
0.1872 
0.1874 
11.34 
11.35 
Siemens 
Immunotech 
Unadjusted 
Adjusted 
971 
971 
6.4292 
6.4287 
1.3189 
1.3284 
11.3355 
11.3703 
0.1965 
0.1979 
11.53 
11.57 
Siemens 
IDS 
Unadjusted 
Adjusted 
970 
970 
5.9935 
5.9931 
1.1925 
1.1954 
10.4296 
10.4400 
0.1777 
0.1782 
10.61 
10.62 
Orion LC-MS 
 
Unadjusted 
Adjusted 
966 
966 
4.7062 
4.7047 
1.2902 
1.2976 
9.5057 
9.5318 
0.1927 
0.1938 
9.70 
9.73 
Orion 
Immunotech 
Unadjusted 
Adjusted 
999 
999 
4.5984 
4.5984 
1.3925 
1.4077 
9.7785 
9.8350 
0.2045 
0.2068 
9.98 
10.04 
Orion 
IDS 
Unadjusted 
Adjusted 
992 
992 
4.1614 
4.1611 
1.2522 
1.2610 
8.8196 
8.8520 
0.1846 
0.1859 
9.00 
9.04 
 
 
Conclusions 
We are suggesting this adjustment for the male elite athlete population only, as the female 
population does not show age dependency. 
The age-adjustment of the score is also beneficial with respect to the normality of the 
scores as the probability plot in figure 4 shows. All scores appear to be normal. 
Another question relates to the appropriateness of the meta-analytic weighted average 
approach - are the age-effects for the six scores similar enough to be validly combined in a 
weighted average? This question is tackled with a heterogeneity analysis. The 2 -test of 
homogeneity is 
 
26
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1
( )
4.37
ˆvar( )
i
i i
 



   
which has a non-significant p-value of 0.498 by 5 df. Hence the approach we have taken 
seems justified (details are given in the Appendix C).  
Distribution of adjusted GH2000 scores 
The construction of the decision limits for GH2000 biomarker methodology is dependent on 
a normal distribution of GH2000 scores among clean athlete. This was assessed using 
probability plotting and the Anderson-Darling test for normality which provided clear 
evidence that all six scores were normally distributed (Figure 4). 
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Figure 4: Probability plots for the six GH2000 scores adjusted for age 
 
The GH2000 and GH2004 teams have previously published the rationale and background to 
the development of decision limits for the GH-2000 biomarker detection method (Powrie et 
al. 2007, Holt et al. 2015) .  
It was always envisaged that a dynamic approach would be taken towards refining the 
decision limits as further data became available. Our recent investigations have shown that 
the age-adjustment in the male discriminant function, which was derived the original 
GH2000 cross-sectional elite athlete study, over-corrects for age in male athletes in our 
more recent cohorts. The effect of this over-correction is to place older male athletes at a 
slight disadvantage compared with their younger peers, for whom the sensitivity of the test 
is reduced. The original age correction for women remained valid in the later cohorts. We 
have used the most recent dataset, on which the current decision limits are based, to add a 
smaller further adjustment to the discriminant function to address this issue. 
It is important to recognise that this age-correction was fitted to a specific cohort of elite 
athletes and only provides an estimate of the true age-correction. Subsequently we have 
found that the male age adjustment overcorrects for age, thus placing older male athletes at 
a small disadvantage. This has been addressed by this analysis. It is reassuring that the age 
correction remained valid for the female athletes in later cohorts 
When undertaking this analysis, we used several principles to guide out work: 1) we wanted 
to ensure that the updated male discriminant function was unaffected by age in order to 
make the test equally fair and effective for athletes of all ages; 2) the change in age 
correction would have a minimal effect on the current decision limits; and 3) a single age 
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adjustment could be applied for all assay pairings. In order to minimise the effect on the 
current decision limits, we used a method that centered the data. By doing so the mean 
GH2000 scores were virtually unaffected. There was a trivial change to the SDs and 
consequently the decision limits, which are based on the mean and SD, were unchanged.  
The age adjustment varies slightly by assay pairing and in order to overcome this, we 
adapted meta-analytical methodology to derive a common age adjustment for all the 
combinations. There was no evidence of heterogeneity between the assay pairings and each 
contributed to the final adjustment equally, providing support for this approach. 
In conclusion, we have created a small further age adjustment for male athletes to correct 
the age bias introduced with the original discriminant formula. This has no effect on the 
decision limits and should be easily introduced into anti-doping testing. 
 
Appendix A: Independence of residuals from model covariates 
Consider a general linear model Y X    where Y X is a n-vector of responses, X is 
the design matrix containing the n-values of p covariates, is a n-vector of errors, and   is a 
p-vector of unknown parameters. Then, the least-squares estimate for   is given as  
 1ˆ )T TX X X Y     
and the vector of residuals * ˆY Y X  . Regressing *Y  on X  leads to the general linear 
model 
 * * *Y X     
and the least-squares estimate of * is given as  
 
* 1 * 1
1 1
1 1 1
1 1
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T T T T
T T T T
T T T T T T
T T T T
X X X Y X X X Y X
X X X Y X X X X Y
X X X Y X X X X X X X Y
X X X Y X X X Y
  
 
  
 
    
   
    
    
  
showing that the residuals are independent from all covariates included in the model. See 
also Sen and Srivastava (1990). 
 
Appendix B: Invariance of the effect estimates with respect to scale transformations 
Consider a general linear model Y X    where Y is a n-vector of responses, X is the 
design matrix containing the n-values of p covariates, is a n-vector of errors, and   is a p-
vector of unknown parameters. Now let A  be an invertible p p  matrix and XA  the 
associated scale-transformation of the design matrix. Then, the least-squares estimate of 
the transformed model * *Y XA   is given as 
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* 1 1 1
1 1 1
ˆ ) ) ( )
) ) .
T T T T T T T T
T T T T
A X XA A X Y X XA A A X Y
X XA X Y A X X X Y
   
  
   
   
  
It follows that the residual with respect to the scale-transformed design matrix 
 
* 1 1
1
ˆ )
)
T T
T T
Y XA Y XAA X X X Y
Y X X X X Y Y X


 

   
    
  
is identical to the residual of the untransformed design matrix.  See also Sen and Srivastava 
1990. As a consequence norming (for example by standard deviations of covariates) of the 
covariates will not change the residuals. 
 
Appendix C: Heterogeneity analysis  
Here we give more details on the meta-analytic approach we have taken. Figure 5 shows the 
various elements involved in the meta-analysis.  
The basic elements are the six GH2000 scores with their age-effects and weights according 
to the inverse variance (similar variance). The two bottom rows show the summary effect 
with and without heterogeneity. Both are virtually identical, as there is no heterogeneity (
2I = 0, no variation due to heterogeneity). In case there is heterogeneity we would consider 
the DerSimonian-Laird approach which incorporates heterogeneity into the weighting 
scheme. In our case, both analyses lead to the same result. All analysis is based on the add-
on package METAN of the statistical software STATA14 (Stata Corp. 2015). 
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Figure 5: Meta-analytic displays including heterogeneity analysis based on METAN, an add-
on package to the statistical software STATA14 
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